Targeting the ubiquitin–proteasome system for cancer therapy

From Bortezomib to other Inhibitors of the Proteasome and Beyond

(2013) Daniela Buac et al.   CURRENT PHARMACEUTICAL DESIGN

Novel Inhibitors of Rad6 Ubiquitin Conjugating Enzyme: Design, Synthesis, Identification, and Functional Characterization

(2013) M. A. Sanders et al.   MOLECULAR CANCER THERAPEUTICS

The Ubiquitin Code

(2012) David Komander et al.   Annual Review of Biochemistry

Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A

(2012) M. Pulvino et al.   BLOOD

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

(2012) Dharminder Chauhan et al.   CANCER CELL

Specific Small Molecule Inhibitors of Skp2-Mediated p27 Degradation

(2012) Lily Wu et al.   CHEMISTRY & BIOLOGY

Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme

(2012) Céline Reverdy et al.   CHEMISTRY & BIOLOGY

Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

(2012) Alexei F. Kisselev et al.   CHEMISTRY & BIOLOGY

HECT and RING finger families of E3 ubiquitin ligases at a glance

(2012) M. B. Metzger et al.   JOURNAL OF CELL SCIENCE

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

(2012) B. Graves et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diverse ubiquitin signaling in NF-κB activation

(2012) Kazuhiro Iwai   TRENDS IN CELL BIOLOGY

An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme

(2011) Derek F. Ceccarelli et al.   CELL

Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes

(2011) Mikael Altun et al.   CHEMISTRY & BIOLOGY

Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer

(2011) S. M. Molineaux   CLINICAL CANCER RESEARCH

Immune and non-immune functions of the immunoproteasome

(2011) Arkhjamil Angeles   Frontiers in Bioscience-Landmark

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

(2011) Pádraig D'Arcy et al.   NATURE MEDICINE

Deubiquitinases in cancer: new functions and therapeutic options

(2011) J M Fraile et al.   ONCOGENE

Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay

(2011) A. G. Herman et al.   Cancer Discovery

Proteasome inhibitors: Dozens of molecules and still counting

(2010) Geoffroy de Bettignies et al.   BIOCHIMIE

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

(2010) D. Chauhan et al.   BLOOD

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

(2010) G. W. Xu et al.   BLOOD

Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage

(2010) Xing Zeng et al.   CANCER CELL

Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis

(2010) V. Kapuria et al.   CANCER RESEARCH

Identification and Characterization of the First Small Molecule Inhibitor of MDMX

(2010) Damon Reed et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications

(2010) L. V. Pham et al.   MOLECULAR CANCER THERAPEUTICS

K11-Linked Polyubiquitination in Cell Cycle Control Revealed by a K11 Linkage-Specific Antibody

(2010) Marissa L. Matsumoto et al.   MOLECULAR CELL

Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ

(2010) James E. Brownell et al.   MOLECULAR CELL

Translating p53 into the clinic

(2010) Chit Fang Cheok et al.   Nature Reviews Clinical Oncology

Inhibition of the Ubiquitin-Proteasome System by Natural Products for Cancer Therapy

(2010) Sachiko Tsukamoto et al.   PLANTA MEDICA

Protein-Protein Interaction Antagonists as Novel Inhibitors of Non-Canonical Polyubiquitylation

(2010) Johanna Scheper et al.   PLoS One

The 26S proteasome: assembly and function of a destructive machine

(2010) Nerea Gallastegui et al.   TRENDS IN BIOCHEMICAL SCIENCES

GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib

(2009) J. Kern et al.   BLOOD

Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and dimerization

(2009) J. Merlet et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins

(2009) Sjoerd J. L. van Wijk et al.   FASEB JOURNAL

Homology Modeling and Docking Analysis of the Interaction between Polyphenols and Mammalian 20S Proteasomes

(2009) Matteo Mozzicafreddo et al.   Journal of Chemical Information and Modeling

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

(2009) D Gutman et al.   LEUKEMIA

NF-κB and cancer: how intimate is this relationship

(2009) Sahdeo Prasad et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

(2009) Ramzi M Mohammad et al.   Molecular Cancer

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

(2009) Teresa A. Soucy et al.   NATURE

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis

(2009) Tony Muchamuel et al.   NATURE MEDICINE

Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy

(2008) Q. Chen et al.   BLOOD

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

(2008) Deborah J. Kuhn et al.   BLOOD

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Argyrin A Reveals a Critical Role for the Tumor Suppressor Protein p27kip1 in Mediating Antitumor Activities in Response to Proteasome Inhibition

(2008) Irina Nickeleit et al.   CANCER CELL

Curcumin Inhibits the Proteasome Activity in Human Colon Cancer Cells In vitro and In vivo

(2008) V. Milacic et al.   CANCER RESEARCH

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

(2008) Shuqing Lü et al.   EXPERIMENTAL HEMATOLOGY

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2

(2008) J. Kitagaki et al.   MOLECULAR CANCER THERAPEUTICS

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA